TY - JOUR
T1 - Neoadjuvant chemotherapy for hypopharyngeal carcinoma
AU - Fujii, Masato
AU - Matsunaga, Tatsuo
AU - Tsunoda, Koichi
AU - Mizutari, Kunio
AU - Fujii, Ryoiti
AU - Masuda, Kanako
AU - Kimura, Satoko
AU - Tomita, Toshiki
AU - Ozawa, Hiroyuki
AU - Fujimine, Takekatsu
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2005
Y1 - 2005
N2 - The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.
AB - The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.
KW - combination chemotherapy
KW - hypopharyngeal carcinoma
KW - neoadjuvant chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85009592456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009592456&partnerID=8YFLogxK
U2 - 10.5981/jjhnc.31.363
DO - 10.5981/jjhnc.31.363
M3 - Article
AN - SCOPUS:85009592456
VL - 31
SP - 363
EP - 368
JO - Japanese Journal of Head and Neck Cancer
JF - Japanese Journal of Head and Neck Cancer
SN - 1349-5747
IS - 3
ER -
